These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 15325030)

  • 1. Is hypocalcemia during therapy with zoledronic acid or other bisphosphonates beneficial to cancer patients?
    Tanvetyanon T
    Med Hypotheses; 2004; 63(4):764-5. PubMed ID: 15325030
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolonged hypocalcemia after zoledronic acid in a patient with metastatic prostate carcinoma: did zoledronic acid trigger osteoblastic activity and avid calcium uptake?
    Ho JW; Sundar S
    Clin Genitourin Cancer; 2012 Mar; 10(1):50-3. PubMed ID: 22245101
    [No Abstract]   [Full Text] [Related]  

  • 3. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration.
    Navarro M; López R; Alaña M; Ocaña A; Leno R; Sánchez F; Fonseca E; Cruz JJ
    J Palliat Med; 2007 Dec; 10(6):1226-7. PubMed ID: 18095793
    [No Abstract]   [Full Text] [Related]  

  • 4. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases.
    Gulley JL; Wu S; Arlen PM; Dahut WL
    Clin Genitourin Cancer; 2007 Sep; 5(6):403-5. PubMed ID: 17956715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypocalcaemia after being given intravenous bisphosphonate.
    Peter R; Mishra V; Fraser WD
    BMJ; 2004 Feb; 328(7435):335-6. PubMed ID: 14764499
    [No Abstract]   [Full Text] [Related]  

  • 6. Zoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
    Patel K; Brahmbhatt V; Ramu V
    Tenn Med; 2005 Feb; 98(2):83-5, 89. PubMed ID: 15779196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
    Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
    Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypocalcemia and azotemia associated with zoledronic acid and interferon alfa.
    Tanvetyanon T; Choudhury AM
    Ann Pharmacother; 2004 Mar; 38(3):418-21. PubMed ID: 14970365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.
    Singh D; Khaira NS; Sekhon JS
    Ann Oncol; 2004 Dec; 15(12):1848. PubMed ID: 15550594
    [No Abstract]   [Full Text] [Related]  

  • 10. Post-surgery severe hypocalcemia in primary hyperparathyroidism preoperatively treated with zoledronic acid.
    Corsello SM; Paragliola RM; Locantore P; Ingraudo F; Ricciato MP; Rota CA; Senes P; Pontecorvi A
    Hormones (Athens); 2010; 9(4):338-42. PubMed ID: 21112866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profound hypocalcaemia after zoledronic acid treatment.
    Nguyen HV; Ingram KB; Beilin J
    Med J Aust; 2005 May; 182(9):494-5. PubMed ID: 15865599
    [No Abstract]   [Full Text] [Related]  

  • 12. Severe symptomatic hypocalcemia in a patient with RDEB treated with intravenous zoledronic acid.
    Perman MJ; Lucky AW; Heubi JE; Azizkhan RG
    Arch Dermatol; 2009 Jan; 145(1):95-6. PubMed ID: 19153360
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
    Cure E; Yuce S; Cure MC
    Minerva Endocrinol; 2013 Jun; 38(2):217-8. PubMed ID: 23732377
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute phase response and mineral status following low dose intravenous zoledronic acid in children.
    Munns CF; Rajab MH; Hong J; Briody J; Högler W; McQuade M; Little DG; Cowell CT
    Bone; 2007 Sep; 41(3):366-70. PubMed ID: 17574945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic effects of zoledronate on cancer neovasculature.
    Metcalf S; Pandha HS; Morgan R
    Future Oncol; 2011 Nov; 7(11):1325-33. PubMed ID: 22044205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
    Jones SG; Dolan G; Lengyel K; Myers B
    Br J Haematol; 2002 Nov; 119(2):576-7. PubMed ID: 12406106
    [No Abstract]   [Full Text] [Related]  

  • 17. Long interval zoledronic acid use in bone metastases.
    Das M
    Lancet Oncol; 2017 Feb; 18(2):e72. PubMed ID: 28089632
    [No Abstract]   [Full Text] [Related]  

  • 18. Short-term safety assessment in the use of intravenous zoledronic acid in children.
    Högler W; Yap F; Little D; Ambler G; McQuade M; Cowell CT
    J Pediatr; 2004 Nov; 145(5):701-4. PubMed ID: 15520785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid.
    Chennuru S; Koduri J; Baumann MA
    Intern Med J; 2008 Aug; 38(8):635-7. PubMed ID: 18284458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.